Table 1.
Baseline Characteristics of Participants by CYP2D6 Metabolizer Phenotypes (n = 2,877)
| Characteristic | CYP2D6 Metabolizer Phenotypes | Total | p | |||
|---|---|---|---|---|---|---|
| Ultra-Rapid and Rapid N = 61 | Normal and Intermediate to Normal N = 1,448 | Intermediate and Intermediate to Poor N = 1,175 | Poor N = 193 | |||
| Total | 61 (2.1) | 1,448 (50) | 1,175 (41) | 193 (6.7) | 2877 | |
| Sex, n (%) | ||||||
| Male | 24 (2.0) | 583 (49) | 494 (42) | 85 (7.2) | 1,186 | 0.66 |
| Female | 37 (2.2) | 865 (51) | 681 (40) | 108 (6.4) | 1,691 | |
| Age | ||||||
| Mean | 63 | 61 | 61 | 63 | 61 | 0.09 |
| SD | 12 | 14 | 13 | 14 | 14 | |
| Race, n (%) | ||||||
| White | 53 (2.0) | 1,355 (50) | 1,119 (41) | 179 (6.6) | 2,706 | 0.02 |
| Black | 0 (0.0) | 6 (55) | 5 (46) | 0 (0.0) | 11 | |
| Asian/Pacific Islander | 0 (0.0) | 18 (78) | 5 (22) | 0 (0.0) | 23 | |
| Unknown | 8 | 69 | 46 | 14 | 137 | |
| Ethnicity, n (%) | ||||||
| Non-Hispanic | 59 (2.1) | 1,428 (50) | 1,160 (41) | 192 (6.8) | 2,839 | 0.39 |
| Hispanic | 2 (5.9) | 17 (50) | 14 (41) | 1 (2.9) | 34 | |
| Unknown | 0 | 3 | 1 | 0 | 0 | |
| Prescription, n (%) | ||||||
| Codeine only | 8 (1.7) | 243 (51) | 191 (40) | 39 (8.1) | 481 | 0.71 |
| Tramadol only | 47 (2.3) | 1,054 (51) | 854 (41) | 130 (6.2) | 2,085 | |
| Both opioids | 6 (1.9) | 151 (49) | 130 (42) | 24 (7.7) | 311 | |
| CYP2D6 activity score | ||||||
| Total | 58 | 1,394 | 1,144 | 192 | 2,788 | |
| Mean | 2.9 | 1.8 | 0.9 | 0 | 1.4 | < 0.001 |
| SD | 0.4 | 0.3 | 0.2 | 0 | 0.7 | |